Non-Dilutive Funding

Genflow Biosciences (GENFF) secured a €4 million non-dilutive grant from Belgium’s Wallonia Region to advance GF-1002, its gene therapy candidate for Metabolic Associated Steatohepatitis (MASH). The grant covers a three-year development program aligned with Genflow’s clinical roadmap. While initial disbursement awaits administrative procedures, the GF-1002 program continues without interruption. Genflow highlights that all project-related expenses incurred in 2025 will be eligible under the grant’s terms.